Unicycive Therapeutics (NASDAQ:UNCY) Stock Rating Upgraded by Wall Street Zen

Unicycive Therapeutics (NASDAQ:UNCY) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other analysts have also recently weighed in on the company. Benchmark reissued a “speculative buy” rating and set a $18.00 price target (up from $15.00) on shares of Unicycive Therapeutics in a report on Tuesday, June 2nd. B. Riley Financial assumed coverage on Unicycive Therapeutics in a report on Friday, May 1st. They set a “buy” rating and a $22.00 price target for the company. Weiss Ratings raised Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Westpark Capital assumed coverage on Unicycive Therapeutics in a report on Thursday, February 19th. They set a “buy” rating for the company. Finally, Guggenheim reissued a “buy” rating and set a $37.00 price target (down from $40.00) on shares of Unicycive Therapeutics in a report on Wednesday, May 13th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.75.

Unicycive Therapeutics Trading Down 5.7%

Shares of NASDAQ UNCY opened at $7.25 on Friday. Unicycive Therapeutics has a 12 month low of $3.71 and a 12 month high of $8.74. The stock has a 50 day moving average of $7.40 and a 200-day moving average of $6.74. The company has a market capitalization of $198.58 million, a P/E ratio of -3.28 and a beta of 1.73.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its earnings results on Tuesday, May 12th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.08). Analysts predict that Unicycive Therapeutics will post -1.34 EPS for the current fiscal year.

Institutional Trading of Unicycive Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Lazard Asset Management LLC bought a new position in shares of Unicycive Therapeutics in the 2nd quarter valued at $55,000. JPMorgan Chase & Co. raised its holdings in shares of Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after buying an additional 21,525 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Unicycive Therapeutics during the 1st quarter worth $161,000. Citadel Advisors LLC acquired a new stake in Unicycive Therapeutics in the third quarter valued at about $182,000. Finally, Bank of America Corp DE boosted its stake in Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after buying an additional 29,378 shares in the last quarter. 40.42% of the stock is owned by institutional investors and hedge funds.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.